ALK – ALK-Abelló A/S

Latest News & Stock Analysis

ALK-Abelló A/S, trading under the ticker ALK on the stock market, is a global pharmaceutical company based in Denmark that specializes in allergy immunotherapy. The company researches, develops, manufactures, and markets products and services for allergy prevention, diagnosis, and treatment. ALK-Abelló’s business model focuses on developing innovative allergy treatments, including sublingual allergy immunotherapy (SLIT) tablets and subcutaneous immunotherapy (SCIT) products, targeting respiratory allergies and asthma. Investors interested in pharmaceutical stocks and market trends in allergy treatments often look to ALK for investment opportunities and news. Stay updated with the latest stock analysis and news on ALK to make informed investment decisions.

Spanish B2B Vehicle Renter Faces Succession Questions
ALK

Spanish B2B Vehicle Renter Faces Succession Questions

by | 19/04/2025 09:00 PM | ALK

🚚 Specializes in flexible B2B vehicle rentals (monthly contracts) in Spain, often with customized vehicles for industrial clients like Telefónica or Ferrovial.

🔄 Operates an efficient vehicle cycle: buys, rents flexibly (average duration 3 years despite monthly option), maintains well, and sells quickly (average 14 days downtime).

⚠️ Faces potential risks from international expansion (Italy) and generational succession within the founding Acebes family, leading the speaker to sell the position.

Read more!